P-974 Treatment of non-small cell lung cancer (NSCLC) patients withthe trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study

✍ Scribed by Sebastian, M.; Schmittel, A.; Friccius-Quecke, H.; Kanniess, F.; Wiewrodt, R.; Lindhoter, H.; Jaeger, M.; Passlick, B.

• Book ID: 123577346
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 140 KB
• Volume: 49
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/S0169-5002(05)81467-9